What is the clinical evidence from this study?

Study design: Cohort. Population: Cardiac Resynchronization Therapy (CRT) patients. Intervention: MADIT-ICD benefit score (MBS). Primary outcome: non-arrhythmic death (HR 1.98, 95% CI 1.23-3.20, p=0.005).

What does this research mean for the field?

The MADIT-ICD benefit score is a significant predictor of non-arrhythmic death and effectively identifies suitable candidates for cardiac resynchronization therapy with defibrillator (CRT-D) among Japanese patients. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

November 8, 2024Open Access

Optimizing Patient Selection for Cardiac Resynchronization Therapy With or Without Defibrillator in a Multicenter Study of Japanese Patients　― Assessment of the MADIT-ICD Benefit Score ―

Key Result

The MADIT-ICD benefit score was a significant predictor of non-arrhythmic death (HR 1.98; 95% CI 1.23-3.20; P=0.005), helping identify suitable candidates for CRT-D among Japanese individuals.

Study Design

Type

Cohort

Multicenter

Yes

Structured PICO

Does the MADIT-ICD benefit score predict ventricular arrhythmias and non-arrhythmic death in Japanese patients undergoing primary prevention cardiac resynchronization therapy?

Population

400 Japanese patients undergoing primary prevention cardiac resynchronization therapy (CRT) device implantation, mean age 64.9 years, 75.5% male. Key inclusion criteria: HF symptoms persisting despite optimal medical therapy, NYHA functional class II-IV, LVEF ≤35%, QRSd ≥120 ms, and no history of prior VT/VF.

Intervention

Stratification by the MADIT-ICD benefit score (MBS) into lowest, intermediate, and highest benefit groups to predict ventricular arrhythmias and non-arrhythmic death.

Comparator

Comparison between the three MADIT-ICD benefit score groups (lowest, intermediate, and highest benefit).

Outcome

Occurrence of ventricular arrhythmias (sustained VT not requiring therapy or appropriate therapy for VT/VF) and non-arrhythmic death during follow-up.hard clinical

The MADIT-ICD benefit score effectively identifies Japanese CRT patients at high risk for ventricular arrhythmias and non-arrhythmic death, aiding in the optimal selection of candidates for concurrent defibrillator therapy.

Main Result

Effect estimate: HR 1.98 (95% CI 1.23-3.20)

p-value: p=0.005

Abstract

BACKGROUND: Although the MADIT-ICD benefit score (MBS) helps select suitable implantable cardioverter defibrillator (ICD) candidates, optimal indicators for cardiac resynchronization therapy (CRT) remain uncertain. Evaluating the applicability of the MBS in Japanese CRT patients is imperative. METHODS AND RESULTS: (HR 1.98; 95% CI 1.23-3.20; P=0.005) were significant predictors of non-arrhythmic death. CONCLUSIONS: The MBS can identify suitable candidates for CRT-D among Japanese individuals.

Perguntar à IA

Bookmark

View Full Paper

Perguntar à IA

Bookmark

View Full Paper

Optimizing Patient Selection for Cardiac Resynchronization Therapy With or Without Defibrillator in a Multicenter Study of Japanese Patients　― Assessment of the MADIT-ICD Benefit Score ―

Key Result

Study Design

Structured PICO

Main Result

Abstract

Cite This Study

Also Consider

Also Consider

Optimizing Patient Selection for Cardiac Resynchronization Therapy With or Without Defibrillator in a Multicenter Study of Japanese Patients ― Assessment of the MADIT-ICD Benefit Score ―

Key Result

Study Design

Structured PICO

Main Result

Abstract

Cite This Study

Also Consider

Also Consider

Optimizing Patient Selection for Cardiac Resynchronization Therapy With or Without Defibrillator in a Multicenter Study of Japanese Patients　― Assessment of the MADIT-ICD Benefit Score ―